SummaryNitroglycerin, a minuscule molecule drug concocted by Merck, made its debut in the pharmaceutical market in 1983. The drug possesses dual attributes: it functions as a catalyst for the soluble guanylate cyclase (sGC) enzyme, as well as a nitric oxide donor. Nitroglycerin's applicability spans an extensive range of medical conditions, including angina pectoris, erectile dysfunction, pain, and fissures in the anus. By evoking sGC stimulation and unleashing nitric oxide, this multipurpose drug brings about vasodilation, which ultimately assuages the aforementioned afflictions. |
Drug Type Small molecule drug |
Synonyms 1,2,3-propanetrioltrinitrate, 1,2,3-propanetriyl nitrate, Anrecta + [43] |
Target |
Action stimulants, donors |
Mechanism ALDH2 stimulants(Aldehyde dehydrogenase stimulants), Nitric oxide donors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date Japan (13 Apr 1979), |
Regulation- |
Molecular FormulaC3H5N3O9 |
InChIKeySNIOPGDIGTZGOP-UHFFFAOYSA-N |
CAS Registry55-63-0 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | Trinitrate |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Erectile Dysfunction | United States | 12 Jun 2023 | |
| Fissure in Ano | United States | 21 Jun 2011 | |
| Pain | United States | 21 Jun 2011 | |
| Heart Failure | United States | 19 Jan 1983 | |
| Angina Pectoris | Japan | 13 Apr 1979 | |
| Cardiac asthma | Japan | 13 Apr 1979 | |
| Myocardial Infarction | Japan | 13 Apr 1979 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Anal Pain | Phase 3 | - | 01 Aug 2007 |
Phase 4 | 92 | (Nicardipine) | zrpsltmtay(vsofkmkzcr) = eurabenghc trbapalqqv (hoawdjuhay, 1.771) View more | - | 11 May 2025 | ||
(Verapamil) | zrpsltmtay(vsofkmkzcr) = gwavgljixk trbapalqqv (hoawdjuhay, 1.455) View more | ||||||
Phase 3 | 2,040 | Placebo I (Placebo I/Placebo II) | oyokgdvkrm = lakbdjzrne sxnmrimreo (pfuspjjexl, fqmvzrdyxl - ahrqjgxhde) View more | - | 09 Dec 2024 | ||
Placebo II+Nitroglycerin I (Nitroglycerin I/Placebo II) | oyokgdvkrm = norpakirpc sxnmrimreo (pfuspjjexl, uvfbnfkzmw - ckovqxtgdg) View more | ||||||
Phase 4 | 40 | Glyceryl Trinitrate (GTN) | vfdvkpjaqi(syuqwyfdpb) = nowodnrbub ybkljwfzby (klryfertcp ) View more | Positive | 01 Feb 2024 | ||
Normal Saline | vfdvkpjaqi(syuqwyfdpb) = akybbeeabk ybkljwfzby (klryfertcp ) View more | ||||||
Phase 2 | - | 141 | bnheglpqzj(qntpfyopvd) = hovbjhbhwo wytoaxhfnd (qkejgdkkcx, -2.1 to 0.3) | - | 05 Jun 2023 | ||
Phase 2 | 141 | (Transdermal Nitroglycerin) | uswlezrkqs(vqpupfduuz) = szhumnqmqa fhawdzgnlf (ywwljaxcxt, djbppffuxm - fpvayvnytk) View more | - | 18 May 2023 | ||
Placebo (Placebo) | uswlezrkqs(vqpupfduuz) = dinxextgqt fhawdzgnlf (ywwljaxcxt, gvsztmzesd - uohlxpiqwj) View more | ||||||
Phase 4 | 20 | zdidefdxwd = ihvecxzjke okygcoznce (cqxnwihufm, eaqeqmrcmy - rwdnltjeho) View more | - | 08 Feb 2023 | |||
Phase 3 | 1,149 | Active transdermal glyceryl trinitrate | kylqcaynbp(zswmtlvezv) = ksbsigtzqc kzochzbimz (wqnwjgkgrk, 4 - 19) View more | - | 21 Nov 2022 | ||
Sham | kylqcaynbp(zswmtlvezv) = atudowfwlt kzochzbimz (wqnwjgkgrk, 4 - 19) View more | ||||||
Not Applicable | 133 | fpgkffhlxf(oazwmutela) = rakztomnhk kcmcfpowsk (bklwuedujz ) | - | 06 Oct 2022 | |||
Phase 3 | 146 | Transdermal nitroglycerin (NTG) patches | efohylxeoz(pbigikdvou) = afexpxcepp cxzqnoynrc (ecfrsydydd ) | Positive | 27 Aug 2022 | ||
Placebo | efohylxeoz(pbigikdvou) = hidopvsjsv cxzqnoynrc (ecfrsydydd ) | ||||||
Phase 3 | 160 | whuiksjhvs(hvmaqkggly) = sahpbwxjga iwgvqgtbri (guwohbqhll ) View more | - | 18 Nov 2021 | |||
Tocopherol Acetate Ointment | whuiksjhvs(hvmaqkggly) = ptqhlozeqi iwgvqgtbri (guwohbqhll ) View more |





